Report
Louis-Clément AZAIS d'UHART
EUR 112.46 For Business Accounts Only

Short term view - NOVARTIS : The support has been breached.

In our previous short term analysis (13/10/2016), we were negative.
We remain negative with a target at 67 CHF and an invalidation level at 73,5 CHF.
The bullish trend is in the course of being reversed.
Arguments :
- The support has been breached.
Underlying
Novartis AG

Novartis is a multinational healthcare group based in Switzerland. Co. provides healthcare solutions that address the evolving needs of patients and societies worldwide. Co.'s broad portfolio includes innovative medicines, eye care products and cost-saving generic pharmaceuticals. Co.'s operations are organized along three operating divisions: Innovative Medicines Division; Sandoz Division; and Alcon Division. Co.'s operations are supported by the Novartis Institutes for BioMedical Research and Novartis Business Services.

Provider
Day By Day
Day By Day

​​DayByDay is an independent research company providing global macro and single stock analysis, recommendation and allocation based purely on behavioural finance methods. Those include long term cycle analysis, sentiment analysis, and technical trigger. DayByDay serves all clients in need of practical and precise publications to make effective market decisions, on any time horizon, from a few hours to a few years.

Analysts
Louis-Clément AZAIS d'UHART

Other Reports on these Companies
Other Reports from Day By Day

ResearchPool Subscriptions

Get the most out of your insights

Get in touch